¼¼°èÀÇ À¯¹æ »ý°Ë ±â±â ½ÃÀå
Breast Biopsy Devices
»óǰÄÚµå : 1513916
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 112 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯¹æ »ý°Ë ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 25¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â 17¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°è À¯¹æ »ý°Ë ±â±â ½ÃÀåÀº 2023-2030³â µ¿¾È ¿¬Æò±Õ 5.7%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇϸç 2030³â±îÁö 25¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ »ý°Ë ¾È³» ½Ã½ºÅÛÀº CAGR 6.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 9¾ï 8,340¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ïµé ±â¹Ý »ý°Ë °Ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 4¾ï 5,440¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.4%·Î ¼ºÀå Àü¸Á

¹Ì±¹ À¯¹æ »ý°Ë ±â±â ½ÃÀåÀº 2023³â 4¾ï 5,440¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â ¿¬Æò±Õ 9.4%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 2030³â¿¡´Â 5¾ï 5,170¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ºÐ¼® ±â°£ µ¿¾È °¢°¢ 1.9%¿Í 6.1%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 3.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯¹æ »ý°Ë ±â±â ¼¼°è ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

À¯¹æ¾ÏÀº ¿©ÀüÈ÷ Àü ¼¼°è ¿©¼ºÀÇ ¾Ï °ü·Ã »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ÀÌ´Â ¾ÏÀ» Á¶±â¿¡ Á¤È®ÇÏ°Ô ¹ß°ßÇϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ¸ç »ç¸Á·üÀ» ³·Ãâ ¼ö ÀÖ´Â È¿°úÀûÀÎ °ËÁø µµ±¸ÀÇ Çʿ伺À» °­Á¶ÇÕ´Ï´Ù. À¯¹æ »ý°Ë ±â±â´Â Á¤È®ÇÑ Á¶±â ¹ß°ßÀÌ »ç¸Á·üÀ» Å©°Ô ³·Ã߱⠶§¹®¿¡ À¯¹æ¾Ï ¹× ÀÌ»ó ¡Èĸ¦ Áø´ÜÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåºñÀÇ ½ÃÀå ¼ºÀåÀº À¯¹æ¾Ï ¹ßº´·üÀÇ Áõ°¡¿Í À¯¹æÃÔ¿µ¼ú, MRI, ÃÊÀ½ÆÄ µî ¿µ»ó±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¿µ»ó À¯µµ »ý°ËÀº ÇöÀç Àǽɽº·¯¿î º´º¯À» Á¤È®ÇÏ°Ô Ç¥ÀûÈ­ÇÏ¿© Àç¼ö¼ú°ú ȯÀÚÀÇ ºÒÆíÇÔÀ» ÃÖ¼ÒÈ­Çϸ鼭 Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. Àü±¹ÀûÀÎ °ËÁø ÇÁ·Î±×·¥µµ ÀÎÁöµµ¸¦ ³ô¿© »ý°Ë¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä Æ®·»µå¿¡´Â Áø°ø º¸Á¶ »ý°Ë ¹× ÀÚµ¿ »ý°ËÃѰú °°Àº ±â¼ú Çõ½ÅÀÌ Æ÷ÇԵǸç, ÀÌ´Â ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ Á¤È®µµ°¡ ³ô°í ħ½À¼ºÀÌ ³·À¸¸ç ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Áø°ø º¸Á¶ ¹Ù´Ã »ý°Ë°ú °°Àº ÃÖ¼Òħ½ÀÀû ¹æ¹ýÀº ºÒÆíÇÔ°ú ÈäÅÍ °¨¼Ò·Î ÀÎÇØ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÚµ¿È­µÈ ÀÏȸ¿ë »ý°Ë Àåºñ´Â °¨¿°À» ¹æÁöÇϰí, ÀÛ¾÷ÀÚÀÇ ÇǷθ¦ ÁÙÀ̰í, È¿À²¼ºÀ» ³ôÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÷´Ü ¿µ»ó Áø´Ü ±â¼ú ¹× AI ±â¼ú°úÀÇ ÅëÇÕÀº Á¶Á÷ äÃë¿¡ °¡Àå ÀûÇÕÇÑ ºÎÀ§¸¦ ½Äº°ÇÏ°í ºÒÇÊ¿äÇÑ »ý°ËÀ» ÁÙÀ̸ç Áø´Ü È¿À²À» ³ô¿© »ý°Ë °úÁ¤À» Á¤±³È­ÇÕ´Ï´Ù.

Á¤¹ÐÀÇ·áµµ »ý°Ë ½ÃÀåÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. »ý°Ë °Ëü¿¡¼­ ¾òÀº ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ÀλçÀÌÆ®¸¦ ÅëÇØ °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖ°í, AI´Â °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÇʰú Áúº´ Ư¼º¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϸç, ÀÓ»óÀÇ¿¡°Ô Á¾ÇÕÀûÀÎ ºÐ¼®°ú ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °³ÀÎÈ­µÈ ÀÇ·á¿Í Á¤¹ÐÀÇ·á·ÎÀÇ ÀüȯÀº »ý°ËÀÇ Áø´Ü ¿ÜÀÇ °¡Ä¡¸¦ ³ôÀ̰í, º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ ¾Ï ÁßÀç·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 23°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Breast Biopsy Devices Market to Reach US$2.5 Billion by 2030

The global market for Breast Biopsy Devices estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$983.4 Million by the end of the analysis period. Growth in the Needle Based Biopsy Guns segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$454.4 Million While China is Forecast to Grow at 9.4% CAGR

The Breast Biopsy Devices market in the U.S. is estimated at US$454.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$551.7 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Breast Biopsy Device Market - Key Trends and Drivers Summarized

Breast cancer remains a leading cause of cancer-related deaths among women worldwide. This underscores the critical need for effective screening tools that can accurately detect cancer early, improving patient outcomes and reducing mortality rates. Breast biopsy devices play a crucial role in diagnosing breast cancer and abnormalities, as accurate early detection can significantly reduce mortality rates. Market growth for these devices is driven by a rising incidence of breast cancer and advancements in imaging technology, such as mammography, MRI, and ultrasound. Image-guided biopsies now allow precise targeting of suspicious lesions, enhancing diagnostic accuracy while minimizing repeat procedures and patient discomfort. National screening programs have also increased awareness, leading to higher demand for biopsies.

Key trends include technological innovations such as vacuum-assisted biopsies and automated biopsy guns, which offer greater accuracy, less invasiveness, and improved patient comfort compared to traditional methods. Minimally invasive methods, such as vacuum-assisted needle biopsies, are gaining popularity due to reduced discomfort and scarring. Automated disposable biopsy devices help prevent infection, reduce operator fatigue, and increase efficiency. Integration with advanced imaging and AI technologies refines the biopsy process by identifying the best sites for tissue extraction, reducing unnecessary biopsies, and enhancing diagnostic efficiency.

Precision medicine is also shaping the biopsy market, as biomarker-driven insights from biopsy samples enable personalized treatment plans. AI helps tailor therapies based on individual genetic profiles and disease characteristics, providing clinicians with comprehensive analyses and actionable insights. This shift towards personalized and precision medicine is enhancing the biopsy's value beyond diagnosis, leading to more effective and individualized cancer interventions.

Select Competitors (Total 23 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â